Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
NCT03866317 · Massachusetts General Hospital · PHASE2 · withdrawn · last registry update 2021-09-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Difficulty recruiting participants” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL17A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-08-15Results posted on the registry: Novartis Pharmaceuticals, secukinumab (NCT03031782)
- 2022-06-28Results posted on the registry: Eli Lilly and Company, Ixekizumab + Placebo (NCT04285229)
- 2022-06-06Results posted on the registry: Ohio State University, Ixekizumab (NCT03137160)
- 2022-05-18Phase 3 first posted: Novartis Pharmaceuticals, Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c. (NCT05380453)
- 2022-05-17Phase 3 first posted: Bio-Thera Solutions, BAT2306 + EU-approved Cosentyx (NCT05377944)
- 2022-04-08Results posted on the registry: Novartis Pharmaceuticals, 150 mg open-label secukinumab + 150 mg double-blinded secukinumab (NCT03350815)
- 2022-04-08Results posted on the registry: Eli Lilly and Company, Ixekizumab (NCT04259346)
- 2022-03-31Results posted on the registry: UCB Biopharma SRL, Bimekizumab (NCT03230292)
- 2022-03-04Results posted on the registry: UCB Biopharma SRL, Bimekizumab (NCT03410992)
- 2022-03-02Results posted on the registry: UCB Biopharma SRL, Bimekizumab + Adalimumab (NCT03412747)
- 2022-02-10Phase 3 first posted: Novartis Pharmaceuticals, Secukinumab (NCT05232864)
- 2022-02-09Results posted on the registry: UCB Biopharma SRL, Bimekizumab + Adalimumab (NCT03248531)
- 2022-02-03Results posted on the registry: UCB Biopharma SRL, Bimekizumab + Ustekinumab (NCT03370133)
- 2022-01-27Also stopped (withdrawn): Matthew C. Baker, tibulizumab (LY3090106) (NCT04563195)
- 2022-01-25Phase 3 first posted: Novartis Pharmaceuticals, Secukinumab (NCT05206591)
- 2021-12-07Results posted on the registry: Novartis Pharmaceuticals, AIN457 (secukinumab) + Placebo (NCT02662985)
- 2021-11-01Results posted on the registry: James G. Krueger, MD, PhD, Secukinumab + Placebo followed by Secukinumab (NCT03131570)
- 2021-10-25Results posted on the registry: UCB Biopharma SRL, Bimekizumab (NCT03010527)
- 2021-09-17Also stopped (terminated): Novartis Pharmaceuticals, AIN457 + ACZ885 (NCT01364389)
- 2021-08-26Results posted on the registry: Novartis Pharmaceuticals, Placebo 2 mL auto-injector + Placebo 1 mL prefilled syringe (NCT03589885)
- 2021-08-25Phase 3 first posted: UCB Biopharma SRL, bimekizumab (NCT05020249)
- 2021-08-25Results posted on the registry: Northwestern University, Secukinumab + Placebo (NCT03041038)
- 2021-08-16Results posted on the registry: Novartis Pharmaceuticals, Experimental : Secukinumab low dose + Experimental: Secukinumab high dose (NCT02471144)
- 2021-08-13Results posted on the registry: Eli Lilly and Company, Ixekizumab (NCT03942042)
- 2021-08-02Results posted on the registry: Bond Avillion 2 Development LP, M1095 (Sonelokimab) + Placebo (NCT03384745)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision